The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation.
 
Rishi Surana
No Relationships to Disclose
 
Valerie S. LeBleu
No Relationships to Disclose
 
J. Jack Lee
Honoraria - AstraZeneca
 
Brandon George Smaglo
Speakers' Bureau - Sirtex Medical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Marker Therapeutics
 
Dan Zhao
No Relationships to Disclose
 
Michael Sangmin Lee
Consulting or Advisory Role - Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Robert A. Wolff
Honoraria - Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Mayela C. Mendt
No Relationships to Disclose
 
Kathleen M. McAndrews
No Relationships to Disclose
 
Sujuan Yang
No Relationships to Disclose
 
Katy Rezvani
Consulting or Advisory Role - Adicet Bio; Avenge Bio; Caribou Biosciences; GEMoaB; GlaxoSmithKline; Takeda; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells
 
Raghu Kalluri
No Relationships to Disclose
 
Anirban Maitra
Patents, Royalties, Other Intellectual Property - Johns Hopkins University has licensed a patent related to pancreatic cancer to Thrive Earlier Detection. I have 1.8% contribution on that patent. No royalties have been received by me.; Royalties from Hangzhou Guangkeande (Cosmos) Biotechnology Company LTD for blood based biomarkers of early pancreatic cancer. I do not own stocks in the company nor do I have any research or grant funding from them.
 
Elizabeth J. Shpall
Honoraria - Bayer; Magenta Therapeutics; Novartis; Partner Therapeutics
Consulting or Advisory Role - • Bayer HealthCare Pharmaceuticals; Adaptimmune; AXIO Research; Magenta Therapeutics; Mesoblast; Novartis; Partner Therapeutics
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)